Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,577,272
  • Shares Outstanding, K 303,950
  • Annual Sales, $ 15,161 M
  • Annual Income, $ 4,272 M
  • 36-Month Beta 1.28
  • Price/Sales 3.47
  • Price/Cash Flow 7.61
  • Price/Book 1.41

Price Performance

See More
Period Period Low Period High Performance
1-Month
160.39 +6.77%
on 06/26/18
173.89 -1.52%
on 07/10/18
+10.64 (+6.62%)
since 06/20/18
3-Month
155.00 +10.48%
on 05/03/18
173.89 -1.52%
on 07/10/18
+6.88 (+4.19%)
since 04/20/18
52-Week
123.73 +38.41%
on 02/09/18
177.51 -3.53%
on 04/19/18
+11.03 (+6.88%)
since 07/20/17

Most Recent Stories

More News
Company News For Jul 11, 2018

Companies In The News are: SHPG,SJM,XRX,PCAR

PCAR : 62.75 (-1.10%)
SJM : 109.47 (-0.09%)
SHPG : 171.25 (-1.00%)
XRX : 25.09 (-0.36%)
Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc

Takeda Pharmaceutical Company Limited:

SHPG : 171.25 (-1.00%)
TKPYY : 21.0250 (-0.66%)
Is Shire (SHPG) a Great Stock for Value Investors?

Let's put Shire (SHPG) stock into this equation and find out if it is a good choice for value-oriented investors right now.

SHPG : 171.25 (-1.00%)
Shire plc : CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI(R) FOR ADULTS WITH VON WILLEBRAND DISEASE

CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI(R) [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE

SHPG : 171.25 (-1.00%)
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

ACRX : 2.95 (unch)
CTLT : 43.98 (+1.48%)
SHPG : 171.25 (-1.00%)
BLRX : 0.91 (unch)
Shire plc: Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas

Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas

SHPG : 171.25 (-1.00%)
Shire Receives U.S. FDA Approval for New State-of-the-Art Plasma Manufacturing Facility Near Covington, Georgia

Shire Receives U.S. FDA Approval for New State-of-the-Art Plasma Manufacturing Facility Near Covington, Georgia

SHPG : 171.25 (-1.00%)
Shire Announces FDA Approval for Label Expansion of CINRYZE(R) for Prevention of Attacks in Pediatric HAE

Shire Announces FDA Approval for Label Expansion of CINRYZE(R) (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients

SHPG : 171.25 (-1.00%)
Stock Performance Review on Sesen Bio and Three Other Biotech

Stock Research Monitor: SHPG, SBOT, and SYN

SBOT : 1.78 (+1.14%)
SHPG : 171.25 (-1.00%)
Barings Acquires Royalty Interest in Recombinant Therapy Vonvendi(R) From Boston Children's Hospital

Barings Alternative Investments, part of Barings LLC, one of the world's leading financial services firms, announced today the acquisition of royalties related to Vonvendi, a treatment for a genetic bleeding...

SHPG : 171.25 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade SHPG with:

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Key Turning Points

2nd Resistance Point 173.70
1st Resistance Point 172.48
Last Price 171.25
1st Support Level 170.47
2nd Support Level 169.68

See More

52-Week High 177.51
Last Price 171.25
Fibonacci 61.8% 156.97
Fibonacci 50% 150.62
Fibonacci 38.2% 144.27
52-Week Low 123.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar